Literature DB >> 8578332

The cost escalation of social health insurance plans in China: its implication for public policy.

X Liu1, W C Hsiao.   

Abstract

China has been alarmed by its rapid rise in health care expenditures of social health insurance schemes. The health care expenditure per person for the 155 million people covered by the Chinese social insurance plans has been rising at an accelerative rate. We analyze why health care cost in China has risen, and show how other nations may benefit from this experience. The annual rate of increase in health expenditure per capita was only 3.1% during 1952 to 1978, the average rate rose to 8.2% during 1978 to 1985 and then 24.4% during 1985 to 1989. We found general inflation explained one-half of the high rates of increase between 1985-1989. Although China introduced patients co-payments in 1985, the residual expenditure per capita (after adjusting for general inflation and aging of the beneficiaries) increased at 7.4% per year due to the adoption of new technology, uses of more expensive drugs and increased quality of services. While we found the expenditure increases in China were largely caused by uncontrollable factors such as general inflation and aging of the population, we also found the change in Chinese hospital financing and payment policy caused rapid adoption of high-tech medicine and abusive usage of more expensive drugs which largely explained the annual increases in expenditures of 7.4% between 1985-1989. Chinese experience also shows that demand strategy (co-payment by patients) had very little effect to contain cost escalation.

Entities:  

Mesh:

Year:  1995        PMID: 8578332     DOI: 10.1016/0277-9536(94)00423-q

Source DB:  PubMed          Journal:  Soc Sci Med        ISSN: 0277-9536            Impact factor:   4.634


  11 in total

1.  Health insurance coverage rates in 9 provinces in China doubled from 1997 to 2006, with a dramatic rural upswing.

Authors:  Hongwei Xu; Susan E Short
Journal:  Health Aff (Millwood)       Date:  2011-12       Impact factor: 6.301

2.  Drug policy in China. Transformations, current status and future prospects.

Authors:  X Liu; S Li
Journal:  Pharmacoeconomics       Date:  1997-07       Impact factor: 4.981

3.  A qualitative study about self-medication in the community among market vendors in Fuzhou, China.

Authors:  Yi Wen; Eli Lieber; Dai Wan; Yuanhao Hong
Journal:  Health Soc Care Community       Date:  2011-06-08

4.  Socioeconomic disparity in healthcare-seeking behavior among Chinese Women with genitourinary symptoms.

Authors:  Qi Zhang; Diane Lauderdale; Shanshan Mou; William I Parish; Edward O Laumann; John Schneider
Journal:  J Womens Health (Larchmt)       Date:  2009-11       Impact factor: 2.681

5.  Urban health insurance reform and coverage in China using data from National Health Services Surveys in 1998 and 2003.

Authors:  Ling Xu; Yan Wang; Charles D Collins; Shenglan Tang
Journal:  BMC Health Serv Res       Date:  2007-03-03       Impact factor: 2.655

6.  The impact of predisposing, enabling, and need factors in utilization of health services among rural residents in Guangxi, China.

Authors:  Yan-Ning Li; Dong-Xiao Nong; Bo Wei; Qi-Ming Feng; Hong-Ye Luo
Journal:  BMC Health Serv Res       Date:  2016-10-19       Impact factor: 2.655

7.  The Research on the Outpatient Cost Adjustment Framework of the Urban Workers in a Southern China City During 2013 to 2015.

Authors:  Na Wang; Ruiming Liu; Jinglin Lu; Peng Quan; Zongfu Mao
Journal:  Inquiry       Date:  2019 Jan-Dec       Impact factor: 1.730

8.  Capacity utilization and the cost of primary care visits: implications for the costs of scaling up health interventions.

Authors:  Taghreed Adam; Steeve Ebener; Benjamin Johns; David B Evans
Journal:  Cost Eff Resour Alloc       Date:  2008-11-13

9.  Econometric estimation of country-specific hospital costs.

Authors:  Taghreed Adam; David B Evans; Christopher JL Murray
Journal:  Cost Eff Resour Alloc       Date:  2003-02-26

10.  Real-world hospital costs for nonchemotherapy drugs and nondrug care associated with platinum-based doublets in the first-line setting for advanced nonsquamous non-small-cell lung cancer in Chinese patients: a retrospective cohort study.

Authors:  Jianhua Chen; Shengqi Wu; Chenping Hu; Yicheng Yang; Narayan Rajan; Yun Chen; Canjuan Yang; Jianfeng Li; Wendong Chen
Journal:  Clinicoecon Outcomes Res       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.